Drug Trial Radar · NCT05248893
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
992
Actual
Start
Feb 25, 2022
Primary completion
Jun 26, 2023
Study completion Jun 26, 2023
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with botulinum toxin. The primary purpose of this study is to evaluate the safety of AGN-151586 over up to three treatments of the study drug to improve the appearance of glabellar lines. AGN-151586 is an investigational product being developed for the treatment of GL. Around 940 to 1100 adult participants with moderate to severe GL will be enrolled in the study in approximately 45 sites in the United States. This is an open-label study in which all participants will receive 5 intramuscular AGN-151586 injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may receive up to 2 additional doses of treatment during the study. Participants will attend regular visits during the study at a study site. The effect of the treatment will be checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.
Conditions
- Glabellar Lines
Interventions
AGN-151586Drug
Powder for Solution for Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: Day 1 (Baseline) to Day 126
- Participants With Post-Baseline Potentially Clinically Important (PCI) Values for Systolic Blood PressureTime frame: Day 1 (Baseline) to Day 126
- Participants With Post-Baseline PCI Values for Diastolic Blood PressureTime frame: Day 1 (Baseline) to Day 126
- Participants With Post-Baseline PCI Values for Heart RateTime frame: Day 1 (Baseline) to Day 126
- Participants With Post-baseline PCI Values in TemperatureTime frame: Day 1 (Baseline) to Day 126
- Participants With Post-baseline PCI Values in Electrocardiogram ParametersTime frame: Day 1 (Baseline) to Day 126
- Presence of Binding and Neutralizing Antidrug Antibodies to AGN-151586Time frame: Day 1 (Baseline) to Day 126
Locations
43 sites in 2 countries. Site status is shown where the registry gives one.
Skin Wellness Dermatology - Homewood /ID# 241233
Birmingham, Alabama
Advanced Research Associates - Glendale /ID# 232245
Glendale, Arizona
Skin Care and Laser Physicians of Beverly Hills /ID# 241237
Los Angeles, California
The Eye Research Foundation /ID# 232229
Newport Beach, California
Cosmetic Laser Dermatology /ID# 243513
San Diego, California
UC San Diego Health - University Center Lane - La Jolla /ID# 241243
San Diego, California
Ava T. Shamban MD - Santa Monica. /ID# 241246
Santa Monica, California
Art of Skin MD /ID# 241244
Solana Beach, California
Moradi MD /ID# 241242
Vista, California
AboutSkin Research, LLC /ID# 241702
Greenwood Village, Colorado
Susan H. Weinkle MD /ID# 233835
Bradenton, Florida
Skin Research Institute LLC /ID# 232240
Coral Gables, Florida
Skin and Cancer Associates, LLP /ID# 232228
Miami, Florida
ForCare Clinical Research /ID# 241229
Tampa, Florida
Hamilton Research, LLC /ID# 241232
Alpharetta, Georgia
Atlanta Biomedical Clinical Research /ID# 241258
Atlanta, Georgia
Meridian Clinical Research Dermatology /ID# 241234
Savannah, Georgia
DeNova Research /ID# 232231
Chicago, Illinois
Advanced Dermatology /ID# 241252
Lincolnshire, Illinois
Laser and Skin Surgery Center of Indiana /ID# 233834
Indianapolis, Indiana
Coleman Center For Cosmetic Dermatologic Surgery /ID# 232230
Metairie, Louisiana
Etre Cosmetic Dermatology and Laser Center /ID# 232235
New Orleans, Louisiana
Visage Dermatology and Aesthetic Center /ID# 241248
Largo, Maryland
Rkmd, Llc /Id# 241239
North Bethesda, Maryland
Michigan Center for Research Company /ID# 241255
Clarkston, Michigan
Rao Dermatology /ID# 243515
Atlantic Highlands, New Jersey
image Dermatology, P.C. /ID# 241227
Montclair, New Jersey
The Rejuva Center /ID# 244285
Latham, New York
Mariwalla Dermatology /ID# 241240
West Islip, New York
Northwest Dermatology Institute /ID# 233498
Portland, Oregon
Perelman Center for Advanced Medicine - /ID# 243966
Philadelphia, Pennsylvania
Sherman Aesthetic Center /ID# 241247
Nashville, Tennessee
Tennessee Clinical Research Center /ID# 241254
Nashville, Tennessee
DermResearch, Inc. Austin, TX /ID# 241228
Austin, Texas
Bellaire Dermatology Associates /ID# 232243
Bellaire, Texas
J&S Studies, Inc. /ID# 241236
College Station, Texas
Dallas Center for Dermatology and Aesthetics /ID# 241245
Dallas, Texas
Swinyer-Woseth Dermatology /ID# 241250
Salt Lake City, Utah
The Education & Research Foundation, Inc. /ID# 241225
Lynchburg, Virginia
Premier Clinical Research /ID# 233836
Spokane, Washington
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.